PHARMASAGA
藥祇生醫股份有限公司
PHARMASAGA is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is PS1 (Phase 2; not yet recruiting, Type 1 Diabetes Mellitus), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| PS1 | — | Phase 2; not yet recruiting | Type 1 Diabetes Mellitus | — | 2026-10-22 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.